Regeneron Stock Today


USD 595.40  4.27  0.72%   

Market Performance
0 of 100
Odds Of Distress
Less than 1
Regeneron Pharmaceuticals is selling for 595.40 as of the 2nd of July 2022. This is a 0.72 percent up since the beginning of the trading day. The stock's open price was 591.13. Regeneron Pharmaceuticals has a very small chance of experiencing financial distress in the next few years, but has generated negative returns over the last 90 days. Equity ratings for Regeneron Pharmaceuticals are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 3rd of May 2022 and ending today, the 2nd of July 2022. Click here to learn more.
Fiscal Year End
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
2nd of April 1991
Health Care
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company was incorporated in 1988 and is headquartered in Tarrytown, New York. Regeneron Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 105.72 M outstanding shares of which 2.16 M shares are at this time shorted by private and institutional investors with about 3.42 trading days to cover. More on Regeneron Pharmaceuticals

Moving together with Regeneron Pharmaceuticals

0.68AAgilent Technologies Fiscal Year End 28th of November 2022 PairCorr
0.85ABCAmerisourcebergen Corp Fiscal Year End 3rd of November 2022 PairCorr
0.85ACBAurora Cannabis Fiscal Year End 26th of September 2022 PairCorr

Moving against Regeneron Pharmaceuticals

0.67DQDaqo New Energy Tech BoostPairCorr
0.57PLABPhotronics Fiscal Year End 14th of December 2022 PairCorr
0.52AVTAvnet Inc Fiscal Year End 10th of August 2022 PairCorr
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores

Regeneron Pharmaceuticals Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. If you consider yourself one of those investors, make sure you clearly understand your entering position. Regeneron Pharmaceuticals' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Regeneron Pharmaceuticals or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
Regeneron Pharmaceuticals generated a negative expected return over the last 90 days
Regeneron Pharmaceuticals is unlikely to experience financial distress in the next 2 years
Regeneron Pharmaceuticals has a strong financial position based on the latest SEC filings
Over 87.0% of the company shares are owned by institutional investors
Latest headline from Regeneron Completes Purchase of Sanofis Stake in Libtayo - Yahoo Finance
ESG SustainabilitySome studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary, Regeneron Pharmaceuticals' sustainability indicators can be used to identify a proper investment strutegies using environmental, social, and governance scores that are crucial to Regeneron Pharmaceuticals' managers, analysts, and investors.
Environment Score
Governance Score
Social Score
President CEO, DirectorLeonard Schleifer
Thematic Ideas
(view all).
Excise Tax ActivitiesAnimal Testing
Average Analyst Recommendation
Analysts covering Regeneron Pharmaceuticals report their recommendations after researching Regeneron Pharmaceuticals' financial statements, talking to executives and customers, or listening in on Regeneron Pharmaceuticals' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Regeneron Pharmaceuticals. The Regeneron consensus assessment is calculated by taking the average forecast from all of the analysts covering Regeneron Pharmaceuticals.
Piotroski F Score
Piotroski F-Score is a popular financial indicator that puts together nine criteria to evaluate the financial strength of Regeneron Pharmaceuticals based on its profitability, leverage, liquidity, source of funds, and operating efficiency. It is an academic score (developed by Joseph Piotroski in 2002) to determine the current strength of Regeneron Pharmaceuticals financial position. Scores of 8 and 9 are usually classified as strong value stocks, whereas scores of 2 or below are considered weak value stocks.
 7 - StrongDetails
Current ValueLast YearChange From Last Year 10 Year Trend
Weighted Average Shares98.1 M105.7 M
Significantly Down
Slightly volatile
Weighted Average Shares Diluted105.3 M112.2 M
Notably Down
Slightly volatile
Net Cash Flow from Operations7.6 B7.1 B
Significantly Up
Slightly volatile
Total Assets27.4 B25.4 B
Significantly Up
Slightly volatile
Total Liabilities7.2 B6.7 B
Significantly Up
Slightly volatile
Current Assets15.1 B14 B
Significantly Up
Slightly volatile
Current Liabilities4.2 B3.9 B
Significantly Up
Slightly volatile
Total Debt349.8 M431 M
Significantly Down
Return on Average Assets40.9137.9139
Significantly Up
Slightly volatile
Gross Margin98.2384.8336
Fairly Up
Slightly volatile
Asset Turnover0.690.7546
Significantly Down
Very volatile
Macroaxis Advice
Unlike general analyst consensus, Macroaxis buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of Regeneron Pharmaceuticals' available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details
Strong BuyUndervalued
Financial Strength
Regeneron Pharmaceuticals' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Regeneron Pharmaceuticals' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
Regeneron Pharmaceuticals' bond ratings measure its overall creditworthiness, which in many ways corresponds to the cost of borrowing for an issuer. These ratings assign a letter grade to all of Regeneron Pharmaceuticals' outstanding corporate bonds that indicate their credit quality. We use reports published by private self-sufficient rating services such as Standard & Poor's or Fitch Ratings Inc. to evaluate a bond issuer's financial strength or its ability to pay a bond's principal and interest.
N/A ( Average Bond Rating ) Not Rated
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Regeneron Pharmaceuticals' financial leverage. It provides some insight into what part of Regeneron Pharmaceuticals' total assets is financed by creditors.
Share Download
Share Download
By using current balance sheet information, investors can analyze the liability, assets, and equity on Regeneron Pharmaceuticals' books and decide whether to invest or hold. Statistics such as return on equity (ROE), debt to equity (D/E) help investors determine how Regeneron Pharmaceuticals deploys its capital and how much of that capital is borrowed.
Regeneron Pharmaceuticals cash flow analysis is essential to understand how it generates and spends money over a specific period. It can also help you figure out where your money is going and how much cash you have available at a given moment. The company currently holds 2.7 B in liabilities with Debt to Equity (D/E) ratio of 0.14, which may suggest the company is not taking enough advantage from borrowing. Regeneron Pharmaceuticals has a current ratio of 3.49, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Regeneron Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Regeneron Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Regeneron Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Regeneron to invest in growth at high rates of return. When we think about Regeneron Pharmaceuticals' use of debt, we should always consider it together with cash and equity.

Operating Cash Flow

7.64 BillionShare
Regeneron Pharmaceuticals (REGN) is traded on NASDAQ Exchange in USA and employs 10,368 people. The company currently falls under 'Large-Cap' category with current market capitalization of 64.27 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Regeneron Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Regeneron Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities. Regeneron Pharmaceuticals conducts business under Healthcare sector and is part of Biotechnology industry. The entity has 105.72 M outstanding shares of which 2.16 M shares are at this time shorted by private and institutional investors with about 3.42 trading days to cover. Regeneron Pharmaceuticals currently holds about 5.69 B in cash with 7.08 B of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 53.5.
Check Regeneron Pharmaceuticals Probability Of Bankruptcy
Regeneron Pharmaceuticals has a total of 105.72 Million outstanding shares. The majority of Regeneron Pharmaceuticals outstanding shares are owned by third-party entities. These institutional holders are usually referred to as non-private investors looking to secure positions in Regeneron Pharmaceuticals to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Regeneron Pharmaceuticals. Please pay attention to any change in the institutional holdings of Regeneron Pharmaceuticals as this could imply that something significant has changed or about to change at the company. Note that regardless of who owns the company, if the true value of the entity is less than the market is willing to pay for it, you may not be able to generate positive returns over time.

Ownership Allocation (%)

Check Regeneron Ownership Details

Regeneron Stock Price Odds Analysis

What are Regeneron Pharmaceuticals' target price odds to finish over the current price? Proceeding from a normal probability distribution, the odds of Regeneron Pharmaceuticals jumping above the current price in 90 days from now is about 86.02%. The Regeneron Pharmaceuticals probability density function shows the probability of Regeneron Pharmaceuticals stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days Regeneron Pharmaceuticals has a beta of 0.7247 indicating as returns on the market go up, Regeneron Pharmaceuticals average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Regeneron Pharmaceuticals will be expected to be much smaller as well. Additionally, the company has a negative alpha, implying that the risk taken by holding this instrument is not justified. Regeneron Pharmaceuticals is significantly underperforming DOW.
  Odds Below 595.4HorizonTargetOdds Above 595.4
13.89%90 days
Based on a normal probability distribution, the odds of Regeneron Pharmaceuticals to move above the current price in 90 days from now is about 86.02 (This Regeneron Pharmaceuticals probability density function shows the probability of Regeneron Stock to fall within a particular range of prices over 90 days) .

Regeneron Stock Institutional Holders

Institutional Holdings refers to the ownership stake in Regeneron Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Regeneron Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Regeneron Pharmaceuticals' value.
InstituionSecurity TypeTotal SharesValue
Fmr LlcCommon Shares10 MB
Blackrock IncCommon Shares9.6 M6.7 B
View Regeneron Pharmaceuticals Diagnostics

Regeneron Pharmaceuticals Historical Income Statement

Regeneron Pharmaceuticals Income Statement is one of the three primary financial statements used for reporting Regeneron's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Regeneron Pharmaceuticals revenue and expense. Regeneron Pharmaceuticals Income Statement primarily focuses on the company's revenues and expenses during a particular period.
Regeneron Pharmaceuticals Interest Expense is quite stable at the moment as compared to the past year. The company's current value of Interest Expense is estimated at 6.65 Million. Net Income is expected to rise to about 8.7 B this year, although the value of Weighted Average Shares will most likely fall to about 98.1 M. View More Fundamentals

Regeneron Stock Against Markets

Picking the right benchmark for Regeneron Pharmaceuticals stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Regeneron Pharmaceuticals stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Regeneron Pharmaceuticals is critical whether you are bullish or bearish towards Regeneron Pharmaceuticals at a given time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Regeneron Pharmaceuticals without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Stock Screener Now


Stock Screener

Find equities using custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
All  Next Launch Module

Regeneron Pharmaceuticals Corporate Directors

Regeneron Pharmaceuticals corporate directors refer to members of a Regeneron Pharmaceuticals board of directors. The board of directors generally takes responsibility for the Regeneron Pharmaceuticals' affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Regeneron Pharmaceuticals' board members must vote for the resolution. The Regeneron Pharmaceuticals board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.
Charles Baker - Independent DirectorProfile
Joseph Goldstein - Independent DirectorProfile
Anthony Coles - Independent DirectorProfile
George Sing - Independent DirectorProfile

Investing Regeneron Pharmaceuticals

You need to understand the risk of investing before taking a position in Regeneron Pharmaceuticals. The danger of trading Regeneron Pharmaceuticals is mainly related to its market volatility and company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Regeneron Pharmaceuticals is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Regeneron Pharmaceuticals. The Shape ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Regeneron Pharmaceuticals is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Additionally, take a look at Your Equity Center. Note that the Regeneron Pharmaceuticals information on this page should be used as a complementary analysis to other Regeneron Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.

Complementary Tools for Regeneron Stock analysis

When running Regeneron Pharmaceuticals price analysis, check to measure Regeneron Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Regeneron Pharmaceuticals is operating at the current time. Most of Regeneron Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Regeneron Pharmaceuticals' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Regeneron Pharmaceuticals' price. Additionally, you may evaluate how the addition of Regeneron Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Commodity Channel Index
Use Commodity Channel Index to analyze current equity momentum
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Transaction History
View history of all your transactions and understand their impact on performance
Fundamental Analysis
View fundamental data based on most recent published financial statements
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Shere Portfolio
Track or share privately all of your investments from the convenience of any device
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Is Regeneron Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Regeneron Pharmaceuticals. If investors know Regeneron will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Regeneron Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth YOY
Market Capitalization
64.9 B
Quarterly Revenue Growth YOY
Return On Assets
Return On Equity
The market value of Regeneron Pharmaceuticals is measured differently than its book value, which is the value of Regeneron that is recorded on the company's balance sheet. Investors also form their own opinion of Regeneron Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Regeneron Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Regeneron Pharmaceuticals' market value can be influenced by many factors that don't directly affect Regeneron Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Regeneron Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine Regeneron Pharmaceuticals value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Regeneron Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.